Six months shy of the PDUFA date for its oral, selective glucocorticoid receptor antagonist relacorilant to treat platinum-resistant ovarian cancer, Corcept Therapeutics Inc. reported a 35% reduction ...

Abbott Laboratories reported fourth quarter sales below expectations before the market opened on Jan. 22, sending the stock down nearly 12% from the prior day's closing. The biggest hits came from ...

The economic and societal implications of the underfunding of women’s health finally reached the agenda of the World Economic ...

Oncogenic KRAS mutations are among the most prevalent driver events in solid tumors, with the KRAS G12D variant constituting the dominant allele in pancreatic ductal adenocarcinoma (PDAC) and a ...

Cancer cells expand through mutations – but not just through mutations. They also change their behavior in the absence of underlying genetic alterations. Such plasticity helps the cells both adapt to ...

A trio of European cancer vaccine specialists have filed progress reports, with advances in technology and targeting, fresh infusions of cash, and off-the-shelf products moving into the clinic. Six ...

Boston Scientific Corp.’s intent to acquire Penumbra Inc. for $14.5 billion will not only allow it to expand its minimal ...

A new method, based on gene editing with oligonucleotides and functional analyses, identifies which variants of DNA repair genes associated with Lynch syndrome are truly harmful and which are not.

Atopia Therapeutics SA has reported new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral ...

The University of Washington has divulged antibody-drug conjugates (ADCs) comprising an antibody targeting HER2 (erbB2) linked to monomethyl auristatin E (MMAE) through a linker. They are described as ...

Sundance Biosciences Inc. has discovered non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of multiple sclerosis.

Rakuten Medical Inc. raised $100 million in a series F round to support late-stage clinical development of ASP-1929, its Alluminox-derived photoimmunotherapy being tested with Keytruda (pembrolizumab) ...